BioCentury | Feb 23, 2021
Product Development

Feb. 22 Quick Takes: Sanofi, J&J in COVID vaccine manufacturing deal; plus AZ, Regeneron-Sanofi, Incyte, Ascletis, Novo-Altasciences, Regor

...company is developing therapies to treat cancer, immune disorders and metabolic diseases.Two priority reviews for Incyte’s...
...to treat graft-versus-host disease (GvHD) and an NDA for ruxolitinib cream to treat atopic dermatitis. Incyte...
BioCentury | Feb 13, 2021
Product Development

Argenx turning cash cow into global commercialization engine

...was most recently chief commercial officer at Incyte Corp....
BioCentury | Feb 9, 2021
Product Development

Feb. 8 Quick Takes: FDA approves TG’s lymphoma therapy; plus uniQure, Astellas, BMS, Viiv, Avrobio and Veru

...treatment option in nearly a decade in Europe since the approval of Jakafi ruxolitinib from Incyte Corp....
BioCentury | Feb 6, 2021
Product Development

Incyte continues layering on new opportunities

...nine months of 2020.But Incyte’s push to diversify its pipeline is beginning to bear fruit. Incyte Corp....
...ourselves.”  Hervé Hoppenot, Incyte A line extension for topical ruxolitinib could soon follow. This half Incyte...
...saying no indication is too small for us.” Hervé Hoppenot, Incyte Under a 2020 deal, Incyte...
BioCentury | Feb 2, 2021
Product Development

Feb. 2 COVID Quick Takes: CanSino vaccine clears interim Phase III hurdle; plus updates from Novartis, CureVac, Lilly, Evotec and Oxford-Imperial College London

...hospitalized with COVID-19, is taking place in 177 U.K. hospitals. Olumiant, an oral JAK-1/JAK-2 inhibitor from Incyte Corp....
BioCentury | Jan 30, 2021
Regulation

Novartis subcutaneous mAb for MS, Incyte and Karyopharm oral cancer therapies backed by CHMP

...therapies to receive a positive opinion from EMA’s CHMP in January were drugs from Novartis, Incyte...
...NASDAQ:KPTI), to treat relapsed and refractory multiple myeloma; and an oral FGFR inhibitor, Pemazyre pemigatinib from Incyte Corp....
...– Exportin 1 Sandi Wong Kesimpta (subQ ofatumumab, subcutaneous ofatumumab) Xpovio, selinexor (ATG-010, KPT-330) Pemazyre, pemigatinib (INCB054828, INCB54828, IBI375) Novartis AG Incyte Corp. Karyopharm...
BioCentury | Jan 22, 2021
Regulation

Jan. 21 Quick Takes: FDA approves ViiV’s long-acting HIV therapy; plus Menarini, Incyte, Moderna, Genentech

...the drug in 2018.July PDUFA data for Incyte’s retifanlimab...
...priority review to a BLA for retifanlimab from Incyte Corp....
...authorization. TARGETSCD123 – IL-3 receptor α Jeff Cranmer ViiV Healthcare Ltd. Menarini Genentech Roche Incyte Moderna Takeda...
BioCentury | Jan 1, 2021
Regulation

Another year of firsts in FDA’s new drug approvals

...in the approvals. Examples include Tabrecta capmatinib from Incyte Corp....
BioCentury | Dec 31, 2020
Deals

Dec. 30 Quick Takes: COVAXX-Aurobindo and Moderna-Recipharm in COVID deals; plus United-Y-mAbs, Zai-Cullinan and Incyte-Cellenkos

...milestones plus high single-digit to low-teen tiered royalties.Incyte...
...trial to treat myelofibrosis. The deal gives Incyte...
...#), ruxolitinib (Generic), Jakavi (Other), Jakafi (Other) CLN-081 (TAS6417) UB-612 Incyte Corp. Cellenkos...
BioCentury | Dec 15, 2020
Product Development

Dec. 14 COVID roundup: Phase III miss for Incyte-Novartis JAK inhibitor; Queensland vaccine program axed; plus Sputnik V final efficacy and Phase II starts for CureVac and Inovio

...Wong, Assistant Editor No benefit in Phase III for Incyte, Novartis JAK inhibitorJakafi ruxolitinib from Incyte Corp....
...also failed to lower mortality and time to recovery.Olumiant baricitinib, another oral JAK-1/JAK-2 inhibitor from Incyte...
...Compound #), INCB018424 (Compound #), INC424 (Compound #), ruxolitinib (Generic), Jakavi (Other), Jakafi (Other) Gam-COVID-Vac Lyo CVnCoV INO-4800 Novartis AG Incyte Corp. University...
Items per page:
1 - 10 of 1318
BioCentury | Feb 23, 2021
Product Development

Feb. 22 Quick Takes: Sanofi, J&J in COVID vaccine manufacturing deal; plus AZ, Regeneron-Sanofi, Incyte, Ascletis, Novo-Altasciences, Regor

...company is developing therapies to treat cancer, immune disorders and metabolic diseases.Two priority reviews for Incyte’s...
...to treat graft-versus-host disease (GvHD) and an NDA for ruxolitinib cream to treat atopic dermatitis. Incyte...
BioCentury | Feb 13, 2021
Product Development

Argenx turning cash cow into global commercialization engine

...was most recently chief commercial officer at Incyte Corp....
BioCentury | Feb 9, 2021
Product Development

Feb. 8 Quick Takes: FDA approves TG’s lymphoma therapy; plus uniQure, Astellas, BMS, Viiv, Avrobio and Veru

...treatment option in nearly a decade in Europe since the approval of Jakafi ruxolitinib from Incyte Corp....
BioCentury | Feb 6, 2021
Product Development

Incyte continues layering on new opportunities

...nine months of 2020.But Incyte’s push to diversify its pipeline is beginning to bear fruit. Incyte Corp....
...ourselves.”  Hervé Hoppenot, Incyte A line extension for topical ruxolitinib could soon follow. This half Incyte...
...saying no indication is too small for us.” Hervé Hoppenot, Incyte Under a 2020 deal, Incyte...
BioCentury | Feb 2, 2021
Product Development

Feb. 2 COVID Quick Takes: CanSino vaccine clears interim Phase III hurdle; plus updates from Novartis, CureVac, Lilly, Evotec and Oxford-Imperial College London

...hospitalized with COVID-19, is taking place in 177 U.K. hospitals. Olumiant, an oral JAK-1/JAK-2 inhibitor from Incyte Corp....
BioCentury | Jan 30, 2021
Regulation

Novartis subcutaneous mAb for MS, Incyte and Karyopharm oral cancer therapies backed by CHMP

...therapies to receive a positive opinion from EMA’s CHMP in January were drugs from Novartis, Incyte...
...NASDAQ:KPTI), to treat relapsed and refractory multiple myeloma; and an oral FGFR inhibitor, Pemazyre pemigatinib from Incyte Corp....
...– Exportin 1 Sandi Wong Kesimpta (subQ ofatumumab, subcutaneous ofatumumab) Xpovio, selinexor (ATG-010, KPT-330) Pemazyre, pemigatinib (INCB054828, INCB54828, IBI375) Novartis AG Incyte Corp. Karyopharm...
BioCentury | Jan 22, 2021
Regulation

Jan. 21 Quick Takes: FDA approves ViiV’s long-acting HIV therapy; plus Menarini, Incyte, Moderna, Genentech

...the drug in 2018.July PDUFA data for Incyte’s retifanlimab...
...priority review to a BLA for retifanlimab from Incyte Corp....
...authorization. TARGETSCD123 – IL-3 receptor α Jeff Cranmer ViiV Healthcare Ltd. Menarini Genentech Roche Incyte Moderna Takeda...
BioCentury | Jan 1, 2021
Regulation

Another year of firsts in FDA’s new drug approvals

...in the approvals. Examples include Tabrecta capmatinib from Incyte Corp....
BioCentury | Dec 31, 2020
Deals

Dec. 30 Quick Takes: COVAXX-Aurobindo and Moderna-Recipharm in COVID deals; plus United-Y-mAbs, Zai-Cullinan and Incyte-Cellenkos

...milestones plus high single-digit to low-teen tiered royalties.Incyte...
...trial to treat myelofibrosis. The deal gives Incyte...
...#), ruxolitinib (Generic), Jakavi (Other), Jakafi (Other) CLN-081 (TAS6417) UB-612 Incyte Corp. Cellenkos...
BioCentury | Dec 15, 2020
Product Development

Dec. 14 COVID roundup: Phase III miss for Incyte-Novartis JAK inhibitor; Queensland vaccine program axed; plus Sputnik V final efficacy and Phase II starts for CureVac and Inovio

...Wong, Assistant Editor No benefit in Phase III for Incyte, Novartis JAK inhibitorJakafi ruxolitinib from Incyte Corp....
...also failed to lower mortality and time to recovery.Olumiant baricitinib, another oral JAK-1/JAK-2 inhibitor from Incyte...
...Compound #), INCB018424 (Compound #), INC424 (Compound #), ruxolitinib (Generic), Jakavi (Other), Jakafi (Other) Gam-COVID-Vac Lyo CVnCoV INO-4800 Novartis AG Incyte Corp. University...
Items per page:
1 - 10 of 1318